Zacks: Analysts Anticipate Dicerna Pharmaceuticals, Inc. (DRNA) Will Post Earnings of -$0.75 Per Share

Equities analysts expect Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to post earnings of ($0.75) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Dicerna Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.81) and the highest estimate coming in at ($0.71). Dicerna Pharmaceuticals posted earnings of ($0.68) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 10.3%. The firm is expected to issue its next earnings report on Monday, November 6th.

Zacks’ earnings per share averages are an average based on a survey of research firms that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.54). Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. The company had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.08 million. During the same period last year, the business posted ($0.75) earnings per share. The company’s quarterly revenue was up 2400.0% on a year-over-year basis.

A number of research firms recently commented on DRNA. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. ValuEngine downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 23rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $6.35.

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) traded up 6.54% on Friday, reaching $3.91. 192,483 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $3.38 and its 200-day moving average price is $3.21. The company’s market capitalization is $81.50 million. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $6.10.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate Dicerna Pharmaceuticals, Inc. (DRNA) Will Post Earnings of -$0.75 Per Share” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/16/zacks-analysts-anticipate-dicerna-pharmaceuticals-inc-drna-will-post-earnings-of-0-75-per-share.html.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Northern Trust Corp grew its position in Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares in the last quarter. Bourgeon Capital Management LLC grew its position in Dicerna Pharmaceuticals by 188.9% during the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 25,500 shares in the last quarter. Paloma Partners Management Co grew its position in Dicerna Pharmaceuticals by 49.7% during the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 53,131 shares in the last quarter. Sabby Management LLC grew its position in Dicerna Pharmaceuticals by 100.0% during the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after purchasing an additional 100,000 shares in the last quarter. Finally, UBS Group AG grew its position in Dicerna Pharmaceuticals by 0.6% during the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 1,599 shares in the last quarter. 55.54% of the stock is currently owned by hedge funds and other institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply